Erscheint 6 Ausgaben pro Jahr
ISSN Druckformat: 0743-4863
ISSN Online: 2162-660X
Indexed in
Inhalational Drug Delivery in Pulmonary Aspergillosis
ABSTRAKT
Pulmonary infections have long represented one of the major threats to humans. These vary from acute to chronic conditions, depending upon the underlying disease of the airways. Pulmonary aspergillosis (PMAP) has raised vital concerns in the immunocompromised patients. The fungal infection is difficult to diagnose in the early stages, often making the disease more complicated. Currently, three classes of antifungal agents are available on the market for the treatment of pulmonary infections. These agents are available in oral and intravenous forms only, which limits the availability of therapeutic concentrations of drug in the lungs for longer durations. Consequently, this leads to therapeutic failure and/or resistance of the organism(s) towards the antifungal agents because the optimum amount of drug does not reach the infection site. To combat the issues associated with the conventional regimens, inhalation of antifungal agents is gaining importance because administration to the lungs offers huge advantages of localized and targeted delivery. A wide range of inhalational devices such as nebulizers, dry powder inhalers, and metered dose inhalers are available on the market to deliver drug molecules to the lungs effectively. However, their clinical utility is limited to conditions such as asthma, chronic obstructive pulmonary disease, and cystic fibrosis only. For a few decades, inhalation therapy has also been gaining importance to treat infectious diseases such as tuberculosis and aspergillosis, though more research efforts are required to make the transition from bench to bedside. The current review provides an explicit account of the potential role of inhalation drug delivery in PMAP.
-
Kaur Ranjot, Kaushik Anupama, Singh Kamalinder K., Katare O. P., Singh Bhupinder, An Efficient and Cost-Effective Nose-Only Inhalational Chamber for Rodents: Design, Optimization and Validation, AAPS PharmSciTech, 21, 3, 2020. Crossref
-
Cheng Shen Nam, Tan Zhi Guang, Pandey Manisha, Srichana Teerapol, Pichika Mallikarjuna Rao, Gorain Bapi, Choudhury Hira, A Critical Review on Emerging Trends in Dry Powder Inhaler Formulation for the Treatment of Pulmonary Aspergillosis, Pharmaceutics, 12, 12, 2020. Crossref
-
Cosio Terenzio, Gaziano Roberta, Zuccari Guendalina, Costanza Gaetana, Grelli Sandro, Di Francesco Paolo, Bianchi Luca, Campione Elena, Retinoids in Fungal Infections: From Bench to Bedside, Pharmaceuticals, 14, 10, 2021. Crossref
-
Kaur Ranjot, Dennison Sarah R., Burrow Andrea J., Rudramurthy Shivaprakash M., Swami Rajan, Gorki Varun, Katare O. P., Kaushik Anupama, Singh Bhupinder, Singh Kamalinder K., Nebulised surface-active hybrid nanoparticles of voriconazole for pulmonary Aspergillosis demonstrate clathrin-mediated cellular uptake, improved antifungal efficacy and lung retention, Journal of Nanobiotechnology, 19, 1, 2021. Crossref
-
Kaur Ranjot, Saini Sumant, Patel Asha, Sharma Teenu, Kaur Ripandeep, Katare O. P, Singh Bhupinder, Developing a Validated HPLC Method for Quantification of Ceftazidime Employing Analytical Quality by Design and Monte Carlo Simulations, Journal of AOAC INTERNATIONAL, 104, 3, 2021. Crossref
-
Kaur Ranjot, Dennison Sarah R, Rudramurthy Shivaprakash M, Katare O P, Sharma Teenu, Singh Bhupinder, Singh Kamalinder K, Aerosolizable Lipid-Nanovesicles Encapsulating Voriconazole Effectively Permeate Pulmonary Barriers and Target Lung Cells, Frontiers in Pharmacology, 12, 2022. Crossref
-
Ito Kazuhiro, Inhaled antifungal therapy: benefits, challenges, and clinical applications, Expert Opinion on Drug Delivery, 19, 7, 2022. Crossref
-
K Deepasree, Venugopal Subhashree, Therapeutic potential of selenium nanoparticles, Frontiers in Nanotechnology, 4, 2022. Crossref